Review Links Thyroid Hormone Suppression to Bone Risks
A new review in Thyroid connects long-term levothyroxine therapy after thyroidectomy to adverse skeletal and other outcomes.
Updated on Nov. 3, 2026 in Nutrition
A review article published in Thyroid linked long-term levothyroxine therapy that suppresses TSH after thyroidectomy to adverse bone outcomes, including lower bone mineral density, osteoporosis and higher fracture risk. The review, which included 35 studies enrolling 11,819 patients, also identified gaps in research on other adverse effects.
Why it matters
Levothyroxine is used long term in some patients after thyroidectomy to suppress TSH and reduce the risk of cancer recurrence, so the findings bear on the trade-off between cancer control and side effects. The authors say developing and validating clinical prediction models could help clinicians estimate individual risk.
The review synthesized 35 studies covering 11,819 patients, with 51.4% examining skeletal outcomes and 40% examining cardiometabolic outcomes. Several gaps remain, and three studies found no link between TSH suppression and atrial fibrillation.
The players
Thyroid
Thyroid is a peer-reviewed journal that publishes research on thyroid disease and its treatment.
The details
Researchers searched three databases for publications from 2011 to February 2026 on postsurgical levothyroxine therapy for differentiated thyroid cancer and related adverse outcomes. Multiple studies reported that increased anxiety and insomnia were linked to lower TSH or higher free T4, while longer treatment duration was linked to osteoporosis or bone loss.
Timeline
2011 to February 2026: Period of studies searched for the review.
November 3, 2026: Article published reporting the review.
Big Picture
The review extends prior work on TSH suppression in differentiated thyroid cancer by consolidating adverse-outcome evidence across multiple body systems. It gives clinicians and researchers a clearer map of where the evidence is strong and where it remains thin.
Patients on long-term levothyroxine after thyroid surgery may want to discuss bone health and other possible effects with their clinicians. The review suggests individual risk estimates may become easier to obtain as prediction models are developed.
The takeaway
Patients on long-term thyroid hormone therapy should ask their clinicians about bone health monitoring and how their individual risk profile compares to the evidence summarized in this review.
Further reading
Explore more on Nutrition for context on hormone and diet-related health topics.
Source note: This article includes information reported by Healio.
